Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.45 |
| ▸ | TNF | P01375 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7182891 | 1.00 | DRD2 (0.52) | DRD2IRAK4TNFGPR119AAK1 | |
| SCHEMBL6156293 | 0.87 | DRD2 (0.52) | DRD2IRAK4TNFGPR119AAK1 | |
| SCHEMBL6156298 | 0.87 | DRD2 (0.52) | DRD2IRAK4TNFGPR119AAK1 | |
| SCHEMBL3179485 | 0.84 | ALOX15 (0.45) | DRD2AAK1KDM1AMAOBBTK | |
| SCHEMBL3179479 | 0.84 | ALOX15 (0.45) | DRD2AAK1KDM1AMAOBBTK | |
| SCHEMBL7176994 | 0.83 | HCAR3 (0.49) | DRD2IRAK4TNFGPR119AAK1 | |
| SCHEMBL7177008 | 0.83 | HCAR3 (0.49) | DRD2IRAK4TNFGPR119AAK1 | |
| SCHEMBL1014626 | 0.83 | BTK (0.44) | DRD2AAK1KDM4DKDM1AMAOB | |
| SCHEMBL15599602 | 0.83 | BTK (0.44) | DRD2AAK1KDM4DKDM1AMAOB | |
| SCHEMBL1014625 | 0.83 | BTK (0.44) | DRD2AAK1KDM4DKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| EP-1196391-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005770-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | DRD2 4674/4885IRAK4 615/4885TNF 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.